AACR: New CAR T cell therapy benefits patients with advanced thyroid cancers
Phase I trial demonstrates lasting responses and encouraging safety profile in two aggressive thyroid cancer subtypes, suggesting further progress for CAR T cell therapy in solid tumors
One patient experienced a complete response, and one patient had a partial response
This type of cancer has limited treatment options, and most patients have a poor prognosis of six months or less
AIC100 is a CAR T cell therapy that targets the ICAM-1 protein...
MD Anderson Research Highlights for April 12, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
MD Anderson and Replay announce FDA clearance of IND application for first-in-class TCR NK cell therapy for multiple myeloma
The University of Texas MD Anderson Cancer Center and Replay today announced that the Food & Drug Administration (FDA) has issued a ‘safe...
MD Anderson researchers present cellular therapy advances at the 2022 ASCO Annual Meeting
ABSTRACTS 7518, 7509, 8009
Promising clinical results with cellular therapies for patients with blood cancers highlight advances being presented by researchers from The University of Texas MD Anderson Cancer Center at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
These findings include long-term outcomes of patients receiving an infusion of brexucabtagene autoleucel (KTE-X19) for mantle cell lymphoma...
MD Anderson and Bellicum announce additional license agreement for use of CaspaCIDe® safety switch
The University of Texas MD Anderson Cancer Center and Bellicum Pharmaceuticals, Inc. today announced a global option and license agreement...
Engineered NK cells can eliminate glioblastoma stem cells
Preclinical research from The University of Texas MD Anderson Cancer Center finds that although glioblastoma stem cells (GSCs) can be targeted...
NK cells with bispecific antibody show activity against lymphoma cells
Cytokine-activated natural killer (NK) cells derived from donated umbilical cord blood, combined with an investigational bispecific antibody...
Antiviral T cells safe and effective for treating debilitating complication common after stem cell transplants
A Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center found that BK virus (BKV)-specific T cells from healthy...
Sherry Adkins receives Brown Foundation Award for Excellence in Oncology Nursing
Sherry Adkins is the recipient of the 2020 Brown Foundation Award for Excellence in Oncology Nursing at The University of Texas MD Anderson...
Combination creates powerful central memory T cells for cellular therapy
Treating T cells harvested from a patient with a combination of an epigenetic drug and a cytokine while expanding the cells in the lab re-programs...